We examined the specificity of BALB/c cytotoxic T (To) cells for respiratory syncytial virus (RSV) components, using recombinant vaccinia viruses (VV) coding for several individual RSV proteins. We found that immunization with the different VVs yielded the following T~ memory cell populations: high levels of RSV-specific To cells were induced with the fusion protein VV, but low levels were induced with VV, coding for the RSV nucleoprotein. T~ cell recognition of attachment glycoprotein, part of the matrix molecule or 1A internal protein was poor. While high levels of fusion proteinspecific To cells were induced by the fusion protein VV, they showed poor crossreactivity between the A2 and 8/60 RSV strains compared with Tc cells primed by RSV infection.
INTRODUCTION
Respiratory syncytial virus (RSV) is designated for vaccine development. It causes severe disease in infants and T cell responses need careful study. Cytotoxic T (To) cells have been described in mouse (Taylor et al., 1984b; Bangham et al., 1985) and in man (Bangham & McMichael, 1986) . Murine Tc cells recognize target cells infected with antigenically distinct human RSV isolates and their role in protection or immunopathology is being examined. So far, it has been shown that transfer of primed T cells can clear a persistent RSV infection in immunodeficient mice . Whatever the role of T~ cells, we aimed to examine their specificity for RSV components for a rational design of vaccines.
In other infections, such as those caused by influenza virus (Bennink et al., 1984; Townsend et al., 1984; Yewdell et al., 1985) , vesicular stomatitis virus (VSV) , reovirus (Finberg et al., 1982) and simian virus 40 (Gooding & O'Connell, 1983) Tc cells have been shown to recognize internal nucleoprotein and surface glycoprotein components, as well as nonstructural components or polymerases (Bennink et al., 1982; Gotch et al., 1987) . In the absence of natural RSV recombinant viruses differing in single proteins, or of easily purified viral components, one approach to the study of To cell specificities has employed vaccinia virus (VV) recombinants expressing individual viral genes. Thus, have recently shown that T~ cells from mice infected with RSV and from humans after natural RSV infection, will recognize target cells infected with VV recombinants expressing the nucleoprotein (N), but will not detectably recognize those expressing the attachment glycoprotein (G).
In this study, we extended our previous study in the mouse by priming with a panel of VV recombinants expressing RSV fusion protein (F), G, matrix protein (M), non-structural protein (1A), or a higher level of N genes and showed that, of the VVs tested, only that expressing F would induce high levels of RSV-specific T~ cells, and that expressing N induced low levels. As the F-specific T¢ cells in BALB/c mice appeared largely subtype-specific, this still left the major antigen(s) for cross-reactive T¢ cells unidentified. (Bangham et al., 1985) and assayed for virus infectivity by a microplaque immunoperoxidase assay (Cannon, 1987) . In brief, HEp-2 ceils were grown in 96-well flat microtitre plates. Stock virus was diluted in 0.5 loglo steps, and 50 pl aliquots were used to infect wells in duplicate for 2 h. After incubation overnight, cells were fixed and stained using monoclonal antibodies (kindly given by Dr B. Fernie, Georgetown University Schools of Medicine and Dentistry, Rockville, Md., U.S.A.) to viral antigens, using rabbit anti-mouse IgG antibody conjugated to peroxidase to form an insoluble product of 3-amino-9-ethylcarbazole. Each infected cell was counted as equivalent to 1 p.f.u, of virus.
Construction and selection of recombinant vaccinia viruses VAG 301 and VN 125 containing respectively the G (G VAC) or N (N VAC) gene cDNA of RSV A2 has been described . Additional recombinant VV vectors were prepared using essentially the protocol of Ball et al. (1986) . VN 333 was a further recombinant containing the N gene cDNA, and it led to higher levels of N protein expression than VN 125 (tested by immunoprecipitation with rabbit anti-RSV sera; A. M. Q. King, S. Langer, L. A. Ball & G. W. Wertz, unpublished data) . VF 325 (low expression) and VF 317 (higher expression of F) were two recombinants containing RSV F gene cDNA (F VAC) in the positive orientation (Wertz et al., 1987) . VNG contained both N and G cDNA which expressed at high levels (NG VAC), VM contained 50~ of the M cDNA (M VAC), and V1A4 contained cDNA coding for the IA protein (1A VAC).
Recombinant VV stocks were grown and titrated in HEp-2 cells as described and stored frozen at -70 °C; they ranged in titre from 2 × l0 T to 3 x 109 p.f.u./ml.
Infection of mice. Female BALB/c mice aged 4 to 12 weeks and bred under specific pathogen-free conditions at this Institute, were infected intranasally (i.n.) with 2 x 105 p.f.u. (50 gl vol.) of RSV A2 strain. Mice receiving vaccinia recombinants were given either 5 × 106 p.f.u.i.n. (50 ~tl) or 2 x 107 p.f.u, intraperitoneally (i.p.) (100 ~tl).
Generation of To cells. Spleen cells from mice infected 3 weeks to 6 months earlier were restimulated in vitro with RSV A2 for 5 days as described (Bangham et al., 1985) . Basic medium was RPMI 1640 plus 10~ foetal calf serum containing penicillin (60 pg/ml), streptomycin (100 p.g/ml), L-glutamine (300 gg/ml) and 2-mercaptoethanol (5 x 10 -5 M). T: cell lines were generated by repeated restimulations in vitro every 7 days, with syngeneic A2-infected X-irradiated (3000 rad) spleen cells. Cultures were supplemented, after four or five restimulations, with 10~ concanavalin A-pulsed rat cell supernatant as a source of interleukin 2. T¢ cell line A2/P8 was derived from splenocytes primed with RSV A2 and restimulated with A2 in vitro eight times. T c cell line F/P8 was derived from splenocytes primed with VF325 and restimulated eight times in vitro with RSV A2.
Target cells and cytotoxicity assay. Target cells for T~ cells were P815 mastocytoma cells or BALB/c fibroblasts (continuous line), infected with RSV strains at a m.o.i, of 0-1 to 2 p.f.u./cell overnight. BCH4 cells are a BALB/c fibroblast line persistently infected with the Long strain of RSV (Fernie et al., 1981) , and obtained from Dr E. J. Stott. BALB/c fibroblast lines were also persistently infected in this laboratory with RSV 18537. Uninfected P815 cells or BALB/c fibroblasts served as controls for non-specific lysis.
T¢ cells were assayed using a 5~Cr release assay as previously described (Bangham et al., 1985) using 104 target cells/well. The percentage specific lysis (L) was calculated as follows: L = [(sample c.p.m.-background c.p.m.)/(total c.p.m. -background c.p.m.)] × 100, where total c.p.m, is the radioactivity released by targets treated with Triton X-100 detergent. Background release of 51Cr ranged from 10 to 30~.
RESULTS

Viral components priming for Tc cells
The virus repertoire of Tc cel3s for RSV proteins could be tested by immunizing mice with recombinant VV coding for individual virus proteins and looking for priming of anti-RSV Tc cells. Fig. 1 illustrates results obtained following immunization with the different vaccinia vectors. Spleen cells of immunized mice were stimulated in vitro with A2 virus for 5 days and lysis of A2-infected target cells was examined. Quite clearly (Fig. 1 a) , F was a major target antigen for Tc cells and immunization i.p. primed for much higher levels of T~ memory cells in spleen than infection i.n. with VF 317. N VAC (VN 333) priming resulted only in low levels (10~) of RSV-specific target lysis (above background) and thus primed only low levels of Tc cells. G VAC (VAG 301) Tc cell priming was marginal, and M VAC or 1A VAC did not induce significant levels of T¢ memory cells (Fig. 1 b) . Fig. 1 (a) 
T c cell cross-reactivity for different RSV strains
We have previously shown that Tc cells primed by RSV A2 infection i.n. recognize target cells equally well whether infected with RSV A2 (group A) or RSV 8/60 (group B) . It was of interest to see whether the same would be true for F-specific To cells primed with F VAC, Fig. 2(b) shows that this was not so and that target cells infected with RSV 8/60 were barely better lysed than uninfected target cells, while T c cells primed by infection i.n. with RSV A2 showed similar levels of lysis to the same batch of RSV A2-or RSV 8/60-infected targets (Fig. 2 a) . We did find that VV-infected mice showed higher non-virus-specific target cell lysis than RSV-infected mice.
Similarly, we tested Tc cell lines restimulated eight times in vitro with A2 virus following priming by A2 or F VAC infection: the Tc cell line from A2-primed mice lysed target cells infected with different RSV strains such as Long, 8/60 or A2 to a similar extent (Fig. 3a) . In contrast, the T~ cell line from F VAC-primed mice showed low lysis of target cells infected with 8/60 virus compared to A2 and Long viruses (Fig. 3b) . In this experiment we also tested lysis of a BALB/c fibroblast line persistently infected with 18537 virus. These targets were barely recognized by the To cell line from F VAC-primed mice and less well but significantly lysed by the A2-primed Tc cell line. Our findings indicate that RSV cross-reactivity varied with Tc cells of different viral specificities. 
DISCUSSION
Our results show that RSV F is a significant target antigen for T~ cells, while T~ cells are poorly primed by N VAC and not significantly primed by N G VAC, although we used a VV recombinant leading to high expression of N for immunization. In a previous report, we also found only low levels of lysis, in RSV A2-primed BALB/c mice, of target cells infected with N VAC , while human T~ cell lines (several times restimulated in vitro) showed strong lysis of N VAC-infected Epstein-Barr virus-transformed syngeneic target cells. We have evidence that there is no problem in expression of N following N VAC infection since N VAC and F VAC induce similar levels of T helper (T~) memory cells (P. J. M. Openshaw, R. M. Pemberton, L. A. Ball, G. W. Wertz & B. A. Askonas, unpublished results). Thus, it appears that at least for BALB/c mice, RSV N is not a major RSV target antigen for Tc cells, but N-specific T~ cells can be selected by repeated restimulation in vitro (M. J. Cannon, unpublished results) and their RSV cross-reactivity will be tested. Thus RSV N may be a better Tc cell target antigen in man compared to mouse although the results were derived from T cell lines restimulated several times in vitro . By analogy with the murine T~ cell response to influenza virus nucleoprotein where there is a high frequency of low responder major histocompatibility complex alleles (Pala & Askonas, 1986) , it is possible that other mouse strains will respond better to N VAC.
We find barely significant lysis of RSV-infected target cells following immunization with G VAC, 1A VAC or M VAC which contained only 5 0~ of the M gene. We know G VAC is expressed since it induced antibodies to G in our mice (P. J. M. Openshaw, unpublished results). Thus, G appears to be a very minor component of the Te cell repertoire, but we find that repeated restimulation with RSV in vitro can lead to some G-specific To cell selection. Pala & Askonas (1985) showed that the ability of C57BL mice to induce anti-influenza K brestricted Tc cells depended upon the route of inoculation (i.p. or i.n.), as well as the cell type used for restimulation. Whilst recognizing the possibility that the efficiency of T~ cell-priming in the present experiments may have been influenced by the route of inoculation (though priming i.n. of F VAC was less effective than priming i.p.), or by the presentation of proteins on cells infected with VV, the very high lysis of target cells infected with different RSV strains by mice primed by A2 infection suggests the possibility that other RSV proteins can be recognized by Tc cells.
Our finding of poor Tc cell-priming for RSV N in mice, even when we used another N VAC leading to higher N expression than that used in the previous paper , contrasted with recognition patterns observed for both influenza virus (Yewdell et al., 1985; Townsend et al., 1984) and VSV , where internal viral nucleoproteins are important target antigens. Thus, Tc cell recognition patterns vary with different viruses.
Our results also emphasized that the actual protein specificity of the To cells determined the extent of cross-reactivity between antigenically different RSV strains. Certainly, F-specific To ceils (following priming of responder mice with F VAC) showed poor cross-reactivity with RSV 8/60 or 18537. In this respect there was concordance with the T~ cell recognition patterns of influenza virus haemagglutinin and VSV G as, in all three instances of glycoprotein recognition, T~ cells appear largely virus strain-specific. However, following infection i.n. with RSV A2, strong cross-reactivity by Tc dells for RSV 8/60 was seen and an F-specific To cell clone derived from mice primed by RSV A2 infection also recognized 8/60 virus (M. J. Cannon, unpublished results). Thus, F-specific T0 cells can be RSV cross-reactive or RSV group-specific and immunizing with F VAC may induce a different Tc cell repertoire compared to infection.
Th cells could also recognize F and this recognition was in part specific for the virus used for priming and in part was cross-reactive for different RSV subgroups (P. J. M. Openshaw, R. M. Pemberton, L. A. Ball, G. W. Wertz and B. A. Askonas, unpublished results) . This contrasted with the highly glycosylated G of RSV, which is poorly recognized by Th ceils and Tc cells . F is also a glycoprotein and expressed at the cell surface, but contains much less oligosaccharide than G (Collins et al., 1984; Wertz et al., 1985) .
Immunization of mice with F VAC will induce neutralizing antibody, prevent fusion of RSVinfected cells and protect against RSV infection (Wertz et al., 1987; Olmsted et al., 1986) , and monoclonal antibodies specific for F protein will protect mice (Taylor et al., 1984a) and cotton rats (Walsh et al., 1983) from RSV challenge infection. This ability of F to stimulate both humoral and cellular arms of the immune response may make it a possible vaccine candidate.
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